Herpes Zoster Market

• Growing incidence of chickenpox to propel market growth

The varicella-zoster virus (VZV), which also causes varicella, reawakens and produces HZ (chickenpox). The WHO estimates that each year there are roughly 4.2 million cases of varicella with serious complications and 4,200 fatalities as a result. Yet, among unvaccinated groups, a subsequent attack rate of more than 70% has been reported. Furthermore, as of 8 June 2022, 1,536 suspected cases with 72 deaths had been recorded from eight countries, citing the WHO, and 59 confirmed cases had been during this same time from six nations.

The rise in the incidence of chickenpox boosts consumer demand for the shingles vaccine and post-herpetic neuralgia treatment, which is propelling the herpes zoster market. Thus, this factor is driving the market CAGR.

However, another major trends boosting the market growth is the emergence of novel vaccinations for disease management. Herpes zoster was entirely managed with pharmacological therapy up until the development of vaccinations. Vendors have concentrated their efforts on creating a number of novel medicines for the management and prevention of shingles, nevertheless. For instance, Merck's V 212 is now undergoing Phase III evaluation as a potential treatment for varicella-zoster. In immunocompromised patients, the molecule has been found to significantly lower the risk of developing herpes zoster by 64%.

In the US, as well as some other European and Asian nations, the vaccine has already finished its Phase III trials. It is anticipated to be released in a few years. These new vaccines should be more effective at treating and preventing herpes zoster. Furthermore, it is anticipated that they will be sold for less than the ones that are already on the market. In turn, this will fuel market expansion over the duration of the forecast. Thus, it is anticipated that this aspect will accelerate herpes zoster market revenue globally.

The Global Herpes Zoster Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 0.21 USD Billion in 2024, it is anticipated to reach 0.37 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 5.34% from 2025 to 2035. Such projections indicate a robust demand for herpes zoster vaccines and treatments, driven by factors such as increasing incidence rates, advancements in vaccine technology, and heightened awareness among healthcare providers and patients alike. The market's expansion reflects a concerted effort to address the public health challenge posed by herpes zoster.

Rising healthcare expenditure across various regions is a significant factor influencing the Global Herpes Zoster Market Industry. Increased investment in healthcare infrastructure and services enables better access to vaccines and treatments for herpes zoster. As governments and private sectors allocate more resources to healthcare, the availability of preventive measures and therapeutic options is likely to improve. This trend is particularly evident in developing countries, where healthcare spending is on the rise. As a result, the market is expected to benefit from enhanced accessibility and affordability of herpes zoster interventions, thereby supporting overall growth.

Recent advancements in vaccine development are poised to enhance the Global Herpes Zoster Market Industry. The introduction of recombinant zoster vaccine (RZV) has shown promising efficacy in preventing herpes zoster and its complications. With the vaccine's approval and subsequent recommendations for use in older adults, vaccination rates are expected to increase. This is particularly relevant as the market is projected to grow to 0.37 USD Billion by 2035, driven by the increasing awareness of the benefits of vaccination. The ongoing research and development efforts in this area may further bolster the market, providing new opportunities for healthcare providers.

The rising incidence of herpes zoster is a primary driver of the Global Herpes Zoster Market Industry. Studies indicate that the lifetime risk of developing herpes zoster is approximately 30 percent, with the incidence increasing significantly with age. In 2024, the market is projected to reach 0.21 USD Billion, reflecting the growing need for effective treatment options. As the global population ages, particularly in developed countries, the demand for vaccines and therapeutic interventions is likely to rise. This trend underscores the importance of addressing herpes zoster as a public health concern, thereby propelling market growth.

Growing awareness and education initiatives regarding herpes zoster are contributing to the expansion of the Global Herpes Zoster Market Industry. Public health campaigns aimed at educating individuals about the risks and complications associated with herpes zoster are likely to lead to increased vaccination rates and early treatment seeking behavior. As healthcare providers emphasize the importance of prevention, the market is expected to experience a compound annual growth rate (CAGR) of 5.34% from 2025 to 2035. This heightened awareness not only encourages individuals to seek vaccination but also fosters a more informed patient population, ultimately driving market growth.

Regulatory support for vaccine implementation plays a crucial role in shaping the Global Herpes Zoster Market Industry. Governments and health organizations are increasingly recognizing the importance of herpes zoster vaccination, leading to favorable policies and guidelines. This regulatory backing not only facilitates vaccine distribution but also encourages healthcare providers to recommend vaccination to eligible populations. As a result, the market is likely to see increased uptake of vaccines, contributing to its growth trajectory. The alignment of public health objectives with regulatory frameworks may further enhance the market's potential, ensuring that effective interventions reach those in need.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America herpes zoster market accounted for USD 0.1 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period due to an increase in herpes zoster cases, growing healthcare costs, an aging population, and herpes zoster technology. The Center for Disease Control and Prevention (CDC) estimates that there are 4 HZ cases per 1,000 people in the United States each year.

The disease affects about 1 in 100 People 60 and older each year.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  HERPES ZOSTER MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe herpes zoster market accounts for the second-largest market share. Government financing and enhanced research and development efforts are credited with the market growth in this area. Herpes zoster is reported to be increasing linearly in frequency across Europe, with yearly incidences ranging from 2.0 to 4.6/1 000 people. Further, the UK herpes zoster market held the largest market share, and the Germany herpes zoster market was the fastest growing market in the region.

Asia Pacific herpes zoster Market is expected to grow at the fastest CAGR from 2024 to 2032 because of rising healthcare costs and increased vaccination awareness. Additionally, the expansion of these regions has been aided by the presence of numerous manufacturing companies. A major advancement is also anticipated for the herpes zoster vaccine in addition to this. Moreover, China herpes zoster market held the largest market share, and the India herpes zoster market was the fastest growing market in the region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the herpes zoster market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the herpes zoster industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global herpes zoster industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, herpes zoster industry has provided medicine with some of the most significant benefits. The herpes zoster market major player such as Astellas Pharma Inc., Foamix Pharmaceuticals, GeneOne Life Science, GlaxoSmithKline plc, Merck & Co., NAL Pharma, Novartis AG, Hoffmann-La Roche Ltd and TSRL Inc.

The global headquarters of the multinational British pharmaceutical and biotechnology business GSK plc, formerly known as GlaxoSmithKline plc, are located in London, England. SmithKline Beecham and Glaxo Wellcome merged to form this company in 2000. In July 2021, the US Food and Drug Administration (FDA) has endorsed Shingrix (Zoster Vaccine Recombinant, Adjuvanted) to prevent herpes zoster in adults 18 years of age and older who are at a higher risk of developing the condition due to immunodeficiency, according to a statement from GSK plc.

With its headquarters in Mumbai, Cipla Ltd is a worldwide pharmaceutical corporation. Cipla focuses on creating medications to treat a variety of illnesses, including arthritis, diabetes, depression, cardiovascular disease, respiratory diseases, and many others. In July 2019, Jiangsu Acebright Pharmaceutical Co. Ltd. and Cipla (EU) Ltd, a U.K.-based wholly-owned subsidiary of the top global pharmaceutical business Cipla Ltd, announced that they had reached an agreement to establish a joint venture company (or "JV Co") in the People's Republic of China.